A Study on Intellectual Property Rights and Access to Medicines

Abstract

The intersection of Intellectual Property Rights (IPRs) and access to medicines remains one of the most debated issues in global health governance. This study examines how patent protection and related intellectual property frameworks influence the availability, affordability, and distribution of essential medicines, particularly in low- and middle-income countries. It analyzes the impact of international agreements such as the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement and the Doha Declaration on Public Health, focusing on their role in balancing innovation incentives with public health imperatives.
The research explores the economic rationale for pharmaceutical patents, emphasizing how exclusivity rights encourage research and development (R&D) investments in new drugs and vaccines. At the same time, it critically evaluates concerns that strong patent regimes may contribute to high medicine prices, delayed generic entry, and unequal access across regions. Special attention is given to policy tools such as compulsory licensing, parallel importation, patent pooling, and voluntary licensing agreements as mechanisms to improve access while preserving innovation incentives.
Using comparative case studies from emerging economies and global health crises, including infectious disease outbreaks, the study highlights the tension between proprietary rights and the right to health. The findings suggest that a flexible and balanced intellectual property framework—supported by international cooperation and domestic regulatory capacity—is essential to ensure equitable access to medicines without undermining pharmaceutical innovation. The paper concludes that strengthening public–private partnerships and leveraging TRIPS flexibilities are critical for achieving sustainable global health outcomes.